Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DP303c in HER2-positive Advanced Breast Cancer
NCT05334810Phase 2Unknown
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- May 2022
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
01
Overview
A Phase 2 trial of DP303c in breast cancer, sponsored by CSPC ZhongQi Pharmaceutical Technology. Status: unknown.
02
Drugs
DP303c
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05334810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05334810.